Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, as well as related services and insights; laboratory testing services for new drugs, vaccines, and medical devices; analytic, on-site prevention, and wellness services; and risk assessment services for the life insurance industry. It also develops, manufactures, and markets diagnostic products, including Simplexa molecular chemistries for testing infectious disease and hospital-acquired infections; HerpeSelect HSV...
3 Giralda Farms
Madison, NJ 07940
Founded in 1967
Quest Diagnostics Inc. Unveils Suite of New Technology Solutions
Apr 9 15
Quest Diagnostics will unveil a suite of new technology solutions during the HIMSS 2015 Annual Conference & Exhibition. The new solutions, featuring Interactive Insights by Care360 reports and IntelliTest Analytics, are designed to promote clinically appropriate test selection and tracking of quality and care metrics, among other benefits, to enhance patient care and outcomes for both the individual patient and large managed populations.
Quest Diagnostics Inc., Quintiles Transnational Holdings Inc. - Special Call
Mar 31 15
To discuss definitive agreement between Quintiles and Quest Diagnostics to form a global clinical trials laboratory services business
Quintiles and Quest Diagnostics to Form Joint Venture to Provide Global Clinical Trials Laboratory Services
Mar 31 15
Quintiles and Quest Diagnostics announced a definitive agreement to form a global clinical trials laboratory services business. By combining the clinical trials laboratory operations of two industry leaders, the new entity will provide customers with the depth of capabilities and end-to-end clinical trial laboratory services required to succeed in the increasingly complex biopharmaceutical industry. The new entity will offer a compelling value proposition to solidify its position as the second-largest central laboratory services company in the world. The joint venture would have generated approximately $575 million in revenues in 2014, and will offer a superior breadth of services and test menu to its customers across all segments of the biopharmaceutical industry – a group that includes all of the top-20 large biopharmaceutical companies. Upon closing of the transaction, Quintiles will own 60% and Quest Diagnostics will own 40% of the new joint venture. Quintiles’ scale, clinical trial expertise, and diverse therapeutic experience coupled with Quest Diagnostics’ operational, scientific and quality excellence, supply chain network and informatics promise greater innovation, quality and value for biopharmaceutical customers. In addition, customers will benefit from a globally scaled and agile business model that is singularly focused on delivering top-quality laboratory services informed by deep medical and clinical knowledge. Clinical, scientific and statistical excellence is becoming increasingly important for successful laboratory work as part of the regulatory approval process. To meet these needs, the entity will draw upon the deep scientific, medical and data expertise of Quintiles and Quest Diagnostics, which together have a team of approximately 3,500 medical doctors, Ph.D.s and biostatisticians as well as cutting-edge experience, expertise and capabilities in the areas of genomics and precision medicine. The new entity also will leverage a number of additional resources from the broader Quintiles and Quest Diagnostics organizations, including the Infosario® technology platform and Quest Diagnostics’ robust data analytics capabilities. Both companies are bioinformatics leaders in their respective fields – positions that have been built upon and honed from diverse experience and data access. Quest Diagnostics draws from 20 billion test results, and Quintiles’ assets include electronic health records representing more than 60 million patient lives and a network of 250,000 clinical investigators. The joint venture will be led by an experienced global management team appointed from Quintiles and Quest Diagnostics. Built upon the strong histories and foundations of quality delivery of its parent organizations, the new entity will provide customers with a variety of advanced testing capabilities and services. These will enable end-to-end companion diagnostic development with regulatory, reimbursement and commercial strategies, to help biopharmaceutical customers’ precision medicine efforts. It also will help enhance quality and efficiency by leveraging Quest Diagnostics’ supply chain that serves approximately half of the physicians and hospitals in the U.S. and includes 2,200 service centers, 3,000 couriers and connectivity solutions used by 250,000 healthcare providers.